Table 1 Patient characteristics (n 45)
Splenic Volume | ||||
|---|---|---|---|---|
Group | Total n % | Not increased | İncreased | P |
Age | ||||
< 65 years | 29 (64) | 16 (69.6) | 13 (59.1) | 0.46 |
≥ 65 years | 16 (36) | 7 (30.4) | 9 (40.9) | |
Gender | ||||
Female | 14 (31) | 13 (56.5) | 19 (86.4) | 0.02 |
Male | 31 (69) | 10 (43.5) | 3 (13.6) | |
ECOG performance status | ||||
0–1 | 34 (76) | 18 (78.3) | 16 (72.7) | 0.66 |
≥ 2 | 11 (24) | 5 (21.7) | 6 (27.3) | |
Nephrectomy | ||||
Yes | 33 (73) | 4 (17.4) | 8 (86.4) | 0.15 |
No | 12 (27) | 19 (82.6) | 14 (13.6) | |
IMDC Risk Group | ||||
Favorable | 7 (16) | 3 (13) | 3 (13.6) | 0.49 |
Intermediate | 36 (80) | 20 (87) | 17 (77.3) | |
Poor | 2 (4) | 0 (0) | 2 (9.1) | |
Tumor Histology | ||||
Clear Cell | 39 (87) | 19 (82.6) | 20 (90.9) | 0.66 |
Non-clear Cell | 6 (13) | 4 (17.4) | 2 (9.1) | |
Body Mass Index Status (kg/ m2) | ||||
< 25 | 22 (49) | 9 (39.1) | 13 (59.1) | 0.42 |
25-29.9 | 14 (31) | 9 (39.1) | 5 (22.7) | |
≥ 30 | 9 (20) | 5 (21.7) | 4 (18.2) | |
Number of prior systemic therapies | ||||
1 | 21 (47) | 9 (39.1) | 13 (59.1) | 0.18 |
2 | 24 (53) | 14 (60.9) | 9 (40.9) | |
Sites of metastases at baseline | ||||
Lung | 24 | 14 | 10 | |
Liver | 7 | 2 | 4 | |
Bone | 14 | 8 | 5 | |
Lymph node | 12 | 7 | 6 | |
Brain | 1 | 0 | 1 | |
Others | 4 | 2 | 2 | |